| A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: results from the … RS Kahn, BL Silverman, L DiPetrillo, C Graham, Y Jiang, J Yin, ... Schizophrenia Research 232, 45-53, 2021 | 28 | 2021 |
| Phase 3 Safety and Tolerability Results of the Combination Olanzapine and Samidorphan in Patients with Schizophrenia: The 1 Year ENLIGHTEN-2-Extension R Kahn, B Silverman, L DiPetrillo, C Graham, Y Jiang, J Yin, A Simmons, ... CNS spectrums 26 (2), 155-156, 2021 | 4 | 2021 |
| Long-term antipsychotic efficacy of olanzapine and samidorphan combination in patients with schizophrenia: pooled analyses from phase 3 studies R Kahn, C Graham, Y Jiang, L DiPetrillo, V Bhupathi, S Yagoda, ... Biological Psychiatry 89 (9), S241-S242, 2021 | 1 | 2021 |
| Long-Term Weight and Metabolic Effects of Olanzapine and Samidorphan Combination in Patients With Schizophrenia: Pooled Analyses From Phase 3 Studies JW Newcomer, Y Jiang, L DiPetrillo, S Yagoda, B Yu, V Bhupathi, ... Biological Psychiatry 89 (9), S242, 2021 | 1 | 2021 |
| A Structured Benefit-Risk Assessment to Evaluate a Combination of Olanzapine and Samidorphan for the Treatment of Schizophrenia and Bipolar I Disorder BD Roy, D McDonnell, B Yu, C Graham, Y Jiang, S Yagoda, V Bhupathi, ... CNS spectrums 27 (2), 233-233, 2022 | | 2022 |
| Utilizing a structured benefit-risk assessment to evaluate a combination of olanzapine and samidorphan for the treatment of schizophrenia and bipolar I disorder B Roy, D McDonnell, B Yu, C Graham, Y Jiang, S Yagoda, V Bhupathi, ... PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 30, 393-393, 2021 | | 2021 |
| Long-Term Safety of Olanzapine and Samidorphan Combination in Patients With Schizophrenia: Pooled Analyses From Phase 2 and 3 Studies V Bhupathi, B Yu, C Graham, L DiPetrillo, J Yin, A Memisoglu, ... Biological Psychiatry 89 (9), S334-S335, 2021 | | 2021 |
